|
KMID : 0941820060160020131
|
|
Korean Journal of Clinical Pharmacy
2006 Volume.16 No. 2 p.131 ~ p.138
|
|
|
Retrospective Evaluation of Heptaplatin Toxicities in Patients with Advanced Gastric Cancer
|
|
Park Mi-Sook
Kang Min-Hee
Lim Sung-Cil
Choi Soon-Ok
Lee Myung-Koo
|
|
|
Abstract
|
|
|
|
Heptaplatin, a new platinum derivative, has several contradicting reports on the nephrotoxicity. Therefore, the aim of this study is to compare the toxicites of heptaplatin-containing regimens in the chemotherapy. This study was performed retrospectively on seventy-seven patients with advanced gastric cancer who did not receive chemotherapy within the last 1 months before taking of heptaplatin- or cisplatin-containing chemotherapy. The 38 patients among total patients was received heptaplatin-containing regimens (26 with SEF regimens: heptaplatin/epirubicin/5-FU, 12 with SF regimens: heptaplatin/5-FU) and the rest 39 patients was received cisplatin-containing regimens (11 with CEF regimens: cisplation/epirubucin/5-FU, 28 with ELF regimens: epirubicin/leucovorin/5-FU). Before and after the chemptherapy serum creatinine(Scr) and proteinuria were mesured by urine stick test in all patient groups. Also Scr was mesured a day before the second cycle and did not vary significantly between groups. However Scr on cycle 3 were significantly higher in SEF and SF groups. In case of priteinuria, it was more frequenct on cycle 1 in heptaplatin/5-FU group. Proteinuria before and after on cycle 2 was not different between the two cisplatin -containing groups, but was more frequent in heptaplatin-containing goups. The reason why the Scr measured was not so different could be because we excluded the patients who received only one cycle of heptaplatin and changed the regimen due to signs of nephrotoxicity. As the results nephrotoxicity such as protienuria was appeared to be more frequent with heptaplatin-treated patients. It suggests that the clinical consequences of the toxicity need to further evaluation and also the modalities to prevent or minimize nephrotoxicity of heptaplatin should be studeid for futher utilization of the drug.
|
|
|
KEYWORD
|
|
|
Heptaplatin, Cicplatin, Chemotherapy, Nephrotoxicity, Gastric cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|